Skip to main content
Premium Trial:

Request an Annual Quote

Abbott and Celera Receive CE Mark for RT-PCR Hepatitis C Test

NEW YORK, July 22 (GenomeWeb News) - Abbott and Celera Diagnostics have received CE Mark certification for a real-time PCR test for monitoring hepatitis C viral load in patients, allowing the test to be marked in the European Union, the companies announced today.


The test, called the Abbot RealTime HCV assay, has been developed for use on the Abbott m2000 system, an automated instrument that uses real-time PCR technology provided by Applied Biosystems.


In June, Abbott and Celera announced CE Mark certification for the Abbot RealTime HIV-1 assay, also developed for use on the m2000 system.


Abbott said additional tests are in development for its m2000 system, including tests for detecting hepatitis B, chlamydia, and gonorrhea.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.